MMDx® for Molecular Biopsy Assessment

Deliver objective and reproducible transplant biopsy assessments

The Value of Gene Expression Profiling

In the post-transplant setting, data derived from the molecular profile of a biopsy can signal ongoing and often subclinical immune-mediated injury, as well as identify acute T cell-mediated rejection, even in samples without histological evidence of inflammation.1 This approach helps to overcome the limitations of conventional biopsy diagnosis, which often relies on histopathology scores that are empirically derived, subjective, and opinion-based.

Having trouble viewing this video? View in browser

 

Manage Post-transplant Treatment With Confidence

MMDx-Heart and MMDx-Kidney complement conventional biopsy processing to improve the assessment of rejection and injury in transplanted organs. These Laboratory Developed Tests use a GeneChip™ Custom Microarray to measure mRNA transcript levels in biopsies along with extensive big data derived from individuals and populations. The MMDx-Heart and MMDx-Lung systems combine these technologies to deliver objective and reproducible transplant biopsy assessments on a molecular level.

 

Order your free Specimen Collection Kit
Click here to order your kit now
Coverage information for post-transplant kidney & heart monitoring
Learn more about medical coverage

“Using an objective scientific approach instead of by eye, we can look at the molecular signature of a biopsy to make a more accurate diagnosis” 1

Andrew Fisher, PhD

Institute of Transplantation at Freeman Hospital
Newcastle Upon Tyne, United Kingdom

How Does the Process Work?

  • mRNA is produced inside transplanted tissue when DNA genes are expressed or active
  • Depending on the risk or severity of organ rejection and injury, particular genes will be activated and produce unique patterns of mRNA
  • Thousands of different mRNA are accurately analyzed. The biopsy report provides a summary of key findings (eg, inflammation, acute kidney injury and atrophy-fibrosis scores and different rejection classifier scores) as well as the overall molecular interpretation

 

From Specimen Collection to Biopsy Report: the MMDx Process

Obtaining results starts with requesting a free Specimen Collection Kit.

The illustration below shows how the sample is analyzed and the biopsy report is generated and made available to clinicians.  

Biopsy sample is packaged and shipped to laboratory

Sample arrives at laboratory

mRNA levels are measured and matched against Reference Set database

Report is posted on secure portal

Doctor is notified of report via email

View sample reports ❯

Kashi Clinical Laboratories, Inc., a CLIA licensed CAP-accredited laboratory located in Portland, Oregon, adopted the MMDx technology. This laboratory-based service will be offered by Kashi in collaboration with Transcriptome Sciences Inc. (TSI) for processing of sample biopsies in the US. Kashi Clinical Laboratories is licensed in all states, including New York, California and Florida.

Molecular Microscope and MMDx are registered trademarks of Transcriptome Sciences Inc.

MMDx is a Laboratory Developed Test offered by Kashi Clinical. MMDx is not intended to provide information for the diagnosis, prevention or treatment of disease or to aid in the clinical decision-making process. This system is not cleared or approved for clinical use by the FDA or approved in the EU as an in vitro diagnostic test, nor is it CE marked.

References
  1. Andrew Fisher, PhD Institute of Transplantation at Freeman Hospital Newcastle Upon Tyne, United Kingdom * https://www.medscape.com/viewarticle/895141